Drug firm Glenmark on Wednesday said it has received approval from the US health regulator to market a generic medication to treat conditions caused by too much acid production in the stomach. Glenmark Specialty SA has received final approval from the US Food & Drug Administration (USFDA) for Esomeprazole Magnesium delayed-release capsules, the drug maker said in a statement. The company’s product is the generic version of Haleon US Holdings LLC’s Nexium.
According to Nielsen syndicated data for the latest 52-week period ending May 18, 2024, the Nexium24 HR delayed-release capsules (20 mg) achieved annual sales of around USD 259.2 million.
Shares of Glenmark were trading 0.55 per cent down at Rs 1,185 apiece on the BSE.
